A Randomized Long-Term Safety Study of Org 50081 in Elderly Outpatients With Chronic Primary Insomnia Examining the Effects of 1.5 mg or 3.0 mg of Org 50081.
Phase of Trial: Phase III
Latest Information Update: 08 Oct 2018
At a glance
- Drugs Esmirtazapine (Primary)
- Indications Insomnia
- Focus Adverse reactions
- Acronyms Jade
- Sponsors Organon; Schering-Plough
- 19 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Oct 2009 Additional lead trial centre and sponsor (Schering-Plough) identified as reported by ClinicalTrials.gov.
- 22 Jul 2009 Planned end date changed from 1 Apr 2010 to 1 Feb 2010 as reported by ClinicalTrials.gov.